Abstract:Axillary staging is commonly performed via sentinel lymph node biopsy for patients with early breast cancer (EBC) presenting with clinically negative axillary lymph nodes (cN0). The present study aimed to investigate the association between axillary lymph node metastasis (ALNM), clinicopathological characteristics of tumors and results from axillary ultrasound (US) scanning. Moreover, a nomogram model was developed to predict the risk for ALNM based on relevant factors. Data from 998 patients who met the inclusion criteria were retrospectively reviewed. These patients were then randomly divided into a training and validation group in a 7:3 ratio. In the training group, receiver operating characteristic curve analysis was used to identify the cutoff values for continuous measurement data. R software was used to identify independent ALNM risk variables in the training group using univariate and multivariate logistic regression analysis. The selected independent risk factors were incorporated into a nomogram. The model differentiation was assessed using the area under the curve (AUC), while calibration was evaluated through calibration charts and the Hosmer‐Lemeshow test. To assess clinical applicability, a decision curve analysis (DCA) was conducted. Internal verification was performed via 1000 rounds of bootstrap resampling. Among the 998 patients with EBC, 228 (22.84%) developed ALNM. Multivariate logistic analysis identified lymphovascular invasion, axillary US findings, maximum diameter and molecular subtype as independent risk factors for ALNM. The Akaike Information Criterion served as the basis for both nomogram development and model selection. Robust differentiation was shown by the AUC values of 0.855 (95% CI, 0.817‐0.892) and 0.793 (95% CI, 0.725‐0.857) for the training and validation groups, respectively. The Hosmer‐Lemeshow test yielded P‐values of 0.869 and 0.847 for the training and validation groups, respectively, and the calibration chart aligned closely with the ideal curve, affirming excellent calibration. DCA showed that the net benefit from the nomogram significantly outweighed both the 'no intervention' and the 'full intervention' approaches, falling within the threshold probability interval of 12‐97% for the training group and 17‐82% for the validation group. This underscores the robust clinical utility of the model. A nomogram model was successfully constructed and validated to predict the risk of ALNM in patients with EBC and cN0 status. The model demonstrated favorable differentiation, calibration and clinical applicability, offering valuable guidance for assessing axillary lymph node status in this population.

Validation of a breast cancer nomogram to predict lymphedema in a Chinese population

Development and validation of a nomogram to predict the risk of breast cancer-related lymphedema among Chinese breast cancer survivors

Development and validation of a nomogram for breast cancer-related lymphedema

Development and Validation of an Intraoperative Nomogram to Predict Breast Cancer-Related Lymphedema Based on the Arm Lymphatics Distribution.

Analysis of the Risk Factors of Breast Cancer-Related Lymphedema and Construction and Evaluation of a Prediction Model

Validation of a nomogram for predicting the risk of lymphedema following contemporary treatment for breast cancer: a large multi-institutional study (KROG 20-05)

A Nomogram To Predict The Probability Of Axillary Lymph Node Metastasis In Female Patients With Breast Cancer In China: A Nationwide, Multicenter, 10-Year Epidemiological Study

Development and Validation of a Nomogram for Axillary Lymph Node Metastasis Risk in Breast Cancer

Elaboration and Validation of a Nomogram Based on Axillary Ultrasound and Tumor Clinicopathological Features to Predict Axillary Lymph Node Metastasis in Patients With Breast Cancer

Predicting Level 2 Axillary Lymph Node Metastasis In A Chinese Breast Cancer Population Post-Neoadjuvant Chemotherapy: Development And Assessment Of A New Predictive Nomogram

Nomogram for Predicting Preoperative Axillary Lymph Node Status in Male Breast Carcinoma: SEER Population-Based Study

A nomogram model for predicting the risk of axillary lymph node metastasis in patients with early breast cancer and cN0 status

Nomogram models for stratified prediction of axillary lymph node metastasis in breast cancer patients (cN0)

Development of nomograms to predict axillary lymph node status in breast cancer patients

Incorporating Ultrasound-Based Lymph Node Staging Significantly Improves the Performance of a Clinical Nomogram for Predicting Preoperative Axillary Lymph Node Metastasis in Breast Cancer

Development and Validation of a Nomogram for Predicting Axillary Lymph Node Metastasis in Breast Cancer

Construction of a nomogram for personalized prediction of lower limb lymphedema risk after cervical cancer surgery

Nomogram for Prediction of Level 2 Axillary Lymph Node Metastasis in Proven Level 1 Node-Positive Breast Cancer Patients

Development and validation of an ultrasonography and clinicopathological features-based nomogram for non-sentinel lymph node metastasis

Risk Factors and a Predictive Nomogram for Non-Sentinel Lymph Node Metastases in Chinese Breast Cancer Patients with One or Two Sentinel Lymph Node Macrometastases and Mastectomy.

Breast cancer-related lymphoedema: Risk factors and prediction model